Increased Frequency of Radiation Therapy Treatment for Small-Cell Lung Cancer Improves Survival Rates

University of Pennsylvania Cancer Center
Last Modified: May 18, 1998

Share article

Lung cancer is the leading cancer killer, with more than 160,000 deaths annually. Radiation therapy is a standard treatment approach for people with lung cancer, and can be used alone or in combination with surgery or chemotherapy. In this study of radiation treatment schedules for patients with small-cell lung cancer, after five years of follow-up, significant improvements in survival were demonstrated when the radiation regimen was given more intensively -- twice-daily over three weeks, rather than once-daily over five weeks. Five-year survival was 28% for patients receiving twice-daily administration, versus 20% for those receiving radiation once-daily.

This result, which represents a major paradigm shift for administering radiation therapy for this disease, shows that the more intensive local treatment in a rapidly-growing tumor improves local control of the cancer, resulting in fewer patient deaths.

[ Original Abstract ]

Significant improvement in progression free survival for non-small-cell lung cancer patients

Jul 7, 2011 - Erlotinib is superior to chemotherapy for improving progression free survival in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations, with acceptable toxicity, according to a study presented at the 14th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer and held from July 3 to 7 in Amsterdam, Netherlands.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More